Patient outcomes after anti TNF-α drugs for Crohn's disease

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 2, 2010, Pages 163-175

  Assasi, Nazila ^a,b   Blackhouse, Gord ^a,b   Xie, Feng ^a,b   Marshall, John K ^c,d   Irvine, E Jan ^e   Gaebel, Kathryn ^a,f   Robertson, Diana ^a,b   Campbell, Kaitryn ^a,b   Hopkins, Rob ^a,b   Goeree, Ron ^a,b,f  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

Adalimumab; Anti TNF drug; Crohns disease; Enbrel ; Etanercept; Humira ; Infliximab; Meta analysis; Remicade

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID DERIVATIVE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTHRALGIA; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; HEART INFARCTION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE INFECTION; INJECTION SITE REACTION; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PHARYNGITIS; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951017769     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.13     Document Type: Review

References (61)

1. Friedman S, Blumberg RS. Inflammatory bowel disease. In: Harrison's Online. Kasper DL, Braunwald E, Fauci AS et al. (Eds). McGraw-Hill Health Professions Division, NY, USA (2008).
2. Bernstein CN, Wajda A, Svenson LW et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am. J. Gastroenterol. 101(7), 1559-1568 (2006). (Pubitemid 43980630)
3. Wong JLH. Inflammatory bowel disease. In: Clinic Handbook: Gastroenterology. Taylor & Francis, Abington, UK (2002).
4. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig. Dis. Sci. 52(11), 2920-2925 (2007). (Pubitemid 47512546)
5. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin. Infect. Dis. 50(4), 473-480 (2010).
6. Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment. Pharmacol. Ther. (2010) (In Press).
7. Rahimi R, Nikfar S, Rahimi F et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig. Dis. Sci. 53(9), 2524-2531 (2008).
8. Gartlehner G, Hansen RA, Thieda P et al. Drug Class Review on Targeted Immune Modulators: Final Report. Oregon Health & Science University, OR, USA (2007).
9. Remicade. In: Notices of Compliance. Health Canada, Canada (2001).
10. Remicade [expansion of indication for Crohn's disease]. In: Notices of Compliance. Health Canada, Canada (2004).
11. Remicade [new indication - treatment of fistulizing Crohn's disease, in adult patients, who have not responded despite a full and adequate course of therapy with conventional treatment]. In: Notices of Compliance. Health Canada, Canada (2005).
12. Remicade [reduction of signs and symptoms and induction and maintenance of clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy]. In: Notices of Compliance. Health Canada, Canada (2006).
13. Humira [new indication: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, including corticosteroid and/or immunosuppressants]. In: Notices of Compliance. Health Canada, Canada (2007).
14. Assasi N, Blackhouse G, Xie F et al. Anti-TNF-a Drugs for Refractory Inflammatory Bowel Disease: Clinical - and Cost-Effectiveness Analyses. Canadian Agency for Drug and Technologies in Health, ON, Canada (2009).
15. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17(1), 1-12 (1996). (Pubitemid 26120810)
16. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Ottawa Health Research Institute, ON, Canada (2008).
17. Sands BE, Abreu MT, Ferry GD et al. Design issues and outcomes in IBD clinical trials. Inflamm. Bowel Dis. 11(Suppl. 1), S22-S28 (2005). (Pubitemid 41572706)
18. Sandborn WJ, Feagan BG, Hanauer SB et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122(2), 512-530 (2002).
19. Principles of meta-analysis. Cochrane handbook for systematic reviews of interventions 5.0.0. In: The Cochrane Library. Higgins JPT, Green S (Eds). John Wiley & Sons Ltd, NJ, USA (2008)
20. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002). (Pubitemid 34621118)
21. D'Haens G, Baert F, van AG et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371(9613), 660-667 (2008). (Pubitemid 351284485)
22. Targan SR, Hanauer SB, Van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337(15), 1029-1035 (1997).
23. Lemann M, Mary JY, Duclos B et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130(4), 1054-1061 (2006).
24. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340(18), 1398-1405 (1999). (Pubitemid 29205403)
25. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004). (Pubitemid 38252535)
26. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117(4), 761-769 (1999). (Pubitemid 29468216)
27. Mantzaris GJ, Ployzou P, Karagiannidis A et al. A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn's disease (CD). Gastroenterology 126(4 Suppl. 2), A54 (2004). (Pubitemid 38917818)
28. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56(9), 1232-1239 (2007). (Pubitemid 47300424)
29. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130(2), 323-333 (2006). (Pubitemid 43202032)
30. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132(1), 52-65 (2007). (Pubitemid 46108762)
31. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: randomized trial. Ann. Intern. Med. 146(12), 829-838 (2007). (Pubitemid 351650483)
32. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5), 1088-1094 (2001). (Pubitemid 33022088)
33. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment. Pharmacol. Ther. 25(6), 675-680 (2007). (Pubitemid 46272520)
34. Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol. 99(10), 1984-1989 (2004). (Pubitemid 39421244)
35. Papadakis KA, Shaye OA, Vasiliauskas EA et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am. J. Gastroenterol. 100(1), 75-79 (2005).
36. Hinojosa J, Gomollon F, Garcia S et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment. Pharmacol. Ther. 25(4), 409-418 (2007). (Pubitemid 46184454)
37. Matsumoto T, Iida M, Motoya S et al. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey. Dis. Colon Rectum 51(6), 916-923 (2008).
38. Schreiber S, Reinisch W, Colombel JF et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of charm. Gastroenterology 132(4 Suppl. 2), A-147 (2007).
39. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126(2), 402-413 (2004). (Pubitemid 38182297)
40. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128(4), 862-869 (2005). (Pubitemid 40523539)
41. Feagan BG, Panaccione R, Sandborn WJ et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135(5), 1493-1499 (2008).
42. Colombel Jf, Rutgeerts P, Yan S et al. Infliximab maintenance treatment results in lower hospitalization rate in Crohn's disease patients. Gastroenterology 122(4 Suppl. 1), A613 (2002).
43. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007). (Pubitemid 47080387)
44. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357(3), 239-250 (2007). (Pubitemid 47080388)
45. Lofberg R, Louis E, Reinisch W, Kron M, Camez A, Pollack P. Adalimumab effectiveness in TNF-antagonist-naive patients and in infliximab nonresponders with Crohn's disease: results from the CARE study. Am. J. Gastroenterol. 103(Suppl.), 1069 (2008).
46. Loftus E Jr, Feagan B, Colombel JF et al. Adalimumab treatment significantly reduces hospitalization risk for TNF-antagonist-naive patients with Crohn's disease. Am J Gastroenterol. 103(Suppl.), (2008).
47. Sandborn W, Rutgeerts P, Reinisch W et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am. J. Gastroenterol. 103, 1117 (2008).
48. Feagan B, McDonald JW, Panaccione R et al. A randomized trial of methotrexate in combination with infliximab for the treatment of crohn's disease. Gastroenterology 135(1), 294-295 (2008).
49. Behm BW , Bickston SJ. Tumor necrosis factor-a antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. (1), CD006893 (2008).
50. D'Haens G, van DS, Van HR et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116(5), 1029-1034 (1999). (Pubitemid 29203012)
51. Peyrin-Biroulet L, Deltenre P, de SN, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6(6), 644-653 (2008). (Pubitemid 351783447)
52. Clark W, Raftery J, Song F et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol. Assess. (Winch. Eng.) 7(3), 1-67 (2003). (Pubitemid 36553179)
53. Bebb JR, Scott BB. Systematic review: how effective are the usual treatments for Crohn's disease? Aliment. Pharmacol. Ther. 20(2), 151-159 (2004). (Pubitemid 38998212)
54. Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed. Pharmacother. 61(1), 75-80 (2007). (Pubitemid 46185874)
55. Tine F, Rossi F, Sferrazza A et al. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Aliment. Pharmacol. Ther. 27(12), 1210-1223 (2008). (Pubitemid 351697273)
56. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 135(5), 1442-1447 (2008).
57. Yun L, Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 3(3), 235-248 (2009).
58. Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm. Bowel Dis. 15(10), 1570-1582 (2009).
59. Krygier DS, Ko HH, Bressler B. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. Expert Rev. Gastroenterol. Hepatol. 3(4), 407-415 (2009).
60. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 372(9632), 67-81 (2008). (Pubitemid 351902263)
61. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 3, 77-97 (2009).